PF-06687234
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PF-06687234, covering 2016-11-07 to 2021-12-28. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission. [Phase 2]